Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Patterson, Sophie ^a,b   Cescon, Angela ^a,n   Samji, Hasina ^a   Chan, Keith ^a   Zhang, Wendy ^a   Raboud, Janet ^c,d   Burchell, Ann N ^c,e   Cooper, Curtis ^f,o   Klein, Marina ^h   Rourke, Sean B ^c,e   Loutfy, Mona ^c   Machouf, Nima ^l,q   Montaner, Julio ^m   Tsoukas, Chris ^g   Hogg, Robert ^b   Kelly, Deborah ^p   Sanche, Stephen ^r   Wong, Alexander ^r   Antoniou, Tony ^s   Bayoumi, Ahmed ^s   Hull, Mark ^a   Nosyk, Bohdan ^b   Cotterchio, Michelle ^c   Goldsmith, Charlie ^b   Guillemi, Silvia ^m   Harrigan, P Richard ^m   Harris, Marianne ^t   Hosein, Sean ^u   Johnston, Sharon ^o   Kendall, Claire ^o   Liddy, Clare ^o   Lima, Viviane ^m   Moore, David ^m   Palmer, Alexis ^b   Phillips, Peter ^m   Rachlis, Anita ^c   Smieja, Marek ^v   Trottier, Benoit ^q   Wainberg, Mark ^g   Walmsley, Sharon ^d   Archibald, Chris ^w   Clement, Ken ^x   Doolittle Romas, Monique ^y   Edmiston, Laurie ^z   Gardner, Sandra ^c   Huskins, Brian ^z   Lawless, Jerry ^aa   Lee, Douglas ^d   Masching, Renee ^x   Tattle, Stephen ^ab   Zahirieh, Alireza ^ac   Allen, Claire ^ad   Calvez, Stryker ^ae   Colley, Guillaume ^a   Chia, Jason ^a   Corsi, Daniel ^af   Gilbert, Louise ^ag   Gataric, Nada ^a   Leslie, Alia ^a   Light, Luciana ^e   Mackie, David ^f   Pexos, Costa ^g   Shurgold, Susan ^a   Szadkowski, Leah ^c   Galanakis, Chrissi ^ah   Yip, Benita ^a   Younger, Jamie ^c   Zhu, Julia ^a   more..

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e ONTARIO HIV TREATMENT NETWORK   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j MAPLE LEAF MEDICAL CLINIC   (Canada)

^k WOMEN S COLLEGE HOSPITAL   (Canada)

^l Clinique Medicale l'Actuel   (Canada)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^o UNIVERSITY OF OTTAWA   (Canada)

^p MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^q UNIVERSITÉ DE MONTRÉAL   (Canada)

^r UNIVERSITY OF SASKATCHEWAN   (Canada)

^s ST MICHAEL'S HOSPITAL   (Canada)

^t ST PAUL S HOSPITAL   (Canada)

^u CATIE   (Canada)

^v MCMASTER UNIVERSITY   (Canada)

^w PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^x Canadian Aboriginal AIDS Network   (Canada)

^y CANADIAN AIDS SOCIETY   (Canada)

^z Canadian Treatment Action Council   (Canada)

^aa UNIVERSITY OF WATERLOO   (Canada)

^ab Canadian Working Group on HIV and Rehabilitation   (Canada)

^ac SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^ad REGINA GENERAL HOSPITAL   (Canada)

^ae SHARE   (Canada)

^af OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^ag Immune Deficiency Treatment Centre   (Canada)

^ah Clinique Medicale L Actuel   (Canada)

more..

Author keywords

Antiretroviral therapy; Canada; CANOC; HIV; Life expectancy; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIGENOUS PEOPLE; LIFE EXPECTANCY; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS; ADOLESCENT; BRITISH COLUMBIA; COMBINATION DRUG THERAPY; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; ONTARIO; QUEBEC; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; BRITISH COLUMBIA; CANADA; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; LIFE EXPECTANCY; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; ONTARIO; QUEBEC; YOUNG ADULT;

EID: 84937205654     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0969-x     Document Type: Article

References (42)

1. Merson MH. The HIV-AIDS Pandemic at 25-The Global Response. N Engl J Med. 2006;354:2414-7.
2. UNAIDS: The Gap Report. 2014 [http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf].
3. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450-4.
4. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-60.
5. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21(6):685-92.
6. Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS. 2009;4(3):194-9.
7. st, 2011. [http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/2011/dec/index-eng.php].
8. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-9.
9. Samji H, Cescon A, Hogg R, Modur S, Althoff K, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8, e81355.
10. Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23(13):1743-53.
11. Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE, McNaghten AD. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS. 2007;21(15):2093-100.
12. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17(4):118-23.
13. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV infected adults. New Engl J Med. 2005;352:48-62.
14. Palmer AK, Klien MB, Raboud J, Cooper C, Hosein S, Loutfy M, et al. Cohort profile: the Canadian Observational Cohort Collaboration. Int J Epidemiol. 2011;40(1):25-32.
15. Chiang CL. The life table and its construction. In: Introduction to stochastic processes in biostatistics. New York: John Wiley and Sons; 1968. p. 189-214.
16. May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol. 2012;41(6):1807-20.
17. Lewden C, Jougla E, Alioum A, Pavillon G, Lievre L, Morlat P, et al. Number of deaths among HIV-infected adults in France in 2000, three-source data capture-recapture estimation. Epidemiol Infect. 2006;134:1345-52.
18. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-16.
19. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grossjurth H, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
20. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa [Letter]. JAMA. 2008;300:506-7.
21. Klein MB, Potter M, Rouleau D, Cox J, Yang H, Saeed S, for the Canadian Co-infection Cohort. Excessive short-term mortality and causes of death in HIV and HCV co-infection: the importance of losses to follow-up. 18th Annual Canadian Conference on HIV/AIDS Research, April 2009.
22. The Human Mortality Database: Canada. Complete data series. 2006. [http://www.mortality.org].
23. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362(9392):1267-74.
24. th Conference on Retroviruses and Opportunistic Infections; March 8 2012. [http://www.retroconference.org/2012b/Abstracts/44961.htm].
25. World Health Organization. Global Health Observatory Data Repository. Life Expectancy Data by Country; 2012. [http://apps.who.int/gho/data/view.main.680?lang=en].
26. Statistics Canada: Life expectancy, at birth and at age 65, by sex and by province and territory, 2007/2009. [http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health72a-eng.htm].
27. Belvedere L, Miller C, Hogg RS. Shifting sands: changing regional and gender-specific patterns of HIV/AIDS mortality in Canada, 1987 to 2008. Can J Public Health. 2012;103(3):202-6.
28. Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009;199(7):991-8.
29. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15(9):1115-23.
30. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011;343:d6016.
31. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol. 2008;168(5):532-40.
32. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333(12):751-6.
33. Laurenco L, Colley G, Nosyk B, Shopin D, Montaner JSG, Lima V. High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada. Plos One. 2014;9(12), e115277.
34. Colley G, Cescon A, Raboud J, Shurgold S, Klein MB, Cooper C, Loutfy MR, Machouf N, Tsoukas C, Montaner JSG, Hogg RS. Continuum of HIV Treatment in Canada, 2003-2012. 23rd Annual Canadian Conference on HIV/ AIDS Research (CAHR 2014); May 2014 [http://www.cahr-acrv.ca/wp-content/uploads/2012/10/CAHR-2014-Abstract-Book.pdf].
35. Martin LJ, Houston S, Yasui Y, Wild TC, Saunders LD. All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active antiretroviral therapy: the impact of aboriginal ethnicity and injection drug use. Can J Public Health. 2011;102(2):90-6.
36. Tyndall MW, Craib KJ, Currie S, Li J, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. JAIDS. 2011;28:351-7.
37. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-9.
38. Cescon A, Chan K, Raboud JM, Burchell AN, Forrest JI, Klein MB, et al. Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history. AIDS. 2014;28(1):121-7.
39. Klein MB, Rollet-Kurhajec KC, Moodie KC, Yaphe S, Tyndall M, Walmsley S, et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). AIDS. 2014;28(13):1957-65.
40. Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410-25.
41. Statistics Canada: Remaining life expectancy at age 25 and probability of survival to age 75, by socio-economic status and Aboriginal ancestry. [http://www.statcan.gc.ca/pub/82-003-x/2011004/article/11560-eng.htm].
42. Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH. Impact of missing data due to selective dropouts in cohort studies and clinical trials. Epidemiology. 2002;13(3):347-55.